ActualitésAssisté par IA

Fujifilm Diosynth Expands UK Presence With Advanced Microbial Manufacturing Plant

Fujifilm Diosynth Biotechnologies launches microbial fermentation facility, tripling production capacity.

Simantini Singh Deo
Par Simantini Singh Deo
Rédacteur principal de contenu
21 août 2024Updated Jun 26, 2025 · 2 min de lecture
Fujifilm Diosynth Expands UK Presence With Advanced Microbial Manufacturing Plant
https://fujifilmdiosynth.com/about/news/fujifilm-diosynth-biotechnologies-celebrates-opening-of-billingham-uk-microbial-manufacturing-facility/
Journalisme assisté par IA
Reviewed by Simantini Singh Deo, Rédacteur principal de contenu

Fujifilm Diosynth Biotechnologies has launched a new microbial fermentation facility in Billingham, significantly boosting its production capacity. The facility now includes a new production line featuring two 4000-liter fermenters, a primary separations suite, and a modular purification suite, effectively tripling its microbial production throughput.

Designed with flexibility in mind, the facility can easily adapt to accommodate future projects, ensuring it meets the evolving needs of Fujifilm Diosynth Biotechnologies' partners while enhancing supply chain resilience. This expansion was partly tailored to support a major pharmaceutical partner in producing a specialized ophthalmic treatment for wet age-related macular degeneration (AMD).

Lars Petersen, President and CEO, Fujifilm Diosynth Biotechnologies, said “With the completion of this project, we are fulfilling our commitment with our partner, and supporting the commercialization of its ophthalmic therapeutic. This is a prime example of our partnership-based business model, a key element in our Partners for Life strategy, to help our customers bring their life-impacting medicines to patients.”

Simantini Singh Deo
Written by
Simantini Singh Deo
Rédacteur principal de contenu

Simantini Singh Deo works on the latest and trending news happening daily in the pharma world.

Discussion

Chargement de la discussion…

Plus dans Pharma News

Tous les articles →